Objective To investigate the status and distribution characteristics of human immuno-deficiency virus(HIV)infection,and the relationship between sample value/cut-off value(S/CO value)and positive test when HIV is tested reactivity by chemiluminescence immunoassay(CLIA).Methods The data of 820 HIV reactivity samples screened by Abbott CLIA in the Department of Clinical Laboratory of Affiliated Hospital of Inner Mongolia Medical University from 2017 to 2023 were selected as the research objects.SPSS22.0 software was used for statistical analysis according to different years,genders and ages.The distribution characteristics of screening reactivity and confirmed positive immunoblot test was compared.The relationship between the confirmed positive,uncertain and negative results and their S/CO values,and the distribution of corresponding bands were retrospectively analyzed.Results From 2017 to 2023,the total number of HIV positive patients decreased first decreased and then increased.The positive rate was 31.95%(262/820),the ratio of males to females was 6.7∶1,the gender difference was statistically significant(χ2=126.8,P<0.05).The ratio of men to women who responded to the screening test was 1.4∶1.The age group with the most confirmed positives for both men and women was 30～50 years old.Divided into five groups according to S/CO value,the positive rate was 0%(0/436)in 1.0≤S/CO≤5.0 group,the positive rate was 6.90%(4/58)in 5.0＜S/CO≤10.0 group,the positive rate was 25.86%(15/58)in 10.0＜S/CO≤50.0 group,the positive rate was 82.09%(110/134)in 50.0＜S/CO≤500.0 group,and the positive rate was 99.25%(133/134)in S/CO＞500.0 group,there was statistical significance in the number of confirmed positives among the five groups(χ2=816.3,P<0.05).There were 473 confirmed negative cases,more women than men,the difference was statistically significant(χ2=98.3,P<0.05),among which the results of S/CO value≤10.0 accounted for 90.49%(428/473).There were 85 uncertain cases,the gender difference was not statistically significant(χ2=1.3,P>0.05),among which the results of S/CO value≤10.0 accounted for 72.94%(62/85).The positive bands gp120 and gp160 appeared in all the results,and p55 appeared the least,accounted for 51.91%(136/262).The uncertain bands were mainly p24,followed by gp160,etc.To a certain extent,the higher the S/CO value of chemiluminescence screening test,the more bands were present when the confirmative test was positive,and the more bands were present when the confirmative test was uncertain.Conclusion The higher the S/CO value of chemiluminescence test for HIV screening test,the higher the positive rate of the confirmation test and the more positive bands,they have practical value for laboratory analysis and early clinical diagnosis.

Objective To investigate the status and distribution characteristics of human immuno-deficiency virus(HIV)infection,and the relationship between sample value/cut-off value(S/CO value)and positive test when HIV is tested reactivity by chemiluminescence immunoassay(CLIA).Methods The data of 820 HIV reactivity samples screened by Abbott CLIA in the Department of Clinical Laboratory of Affiliated Hospital of Inner Mongolia Medical University from 2017 to 2023 were selected as the research objects.SPSS22.0 software was used for statistical analysis according to different years,genders and ages.The distribution characteristics of screening reactivity and confirmed positive immunoblot test was compared.The relationship between the confirmed positive,uncertain and negative results and their S/CO values,and the distribution of corresponding bands were retrospectively analyzed.Results From 2017 to 2023,the total number of HIV positive patients decreased first decreased and then increased.The positive rate was 31.95%(262/820),the ratio of males to females was 6.7∶1,the gender difference was statistically significant(χ2=126.8,P<0.05).The ratio of men to women who responded to the screening test was 1.4∶1.The age group with the most confirmed positives for both men and women was 30～50 years old.Divided into five groups according to S/CO value,the positive rate was 0%(0/436)in 1.0≤S/CO≤5.0 group,the positive rate was 6.90%(4/58)in 5.0＜S/CO≤10.0 group,the positive rate was 25.86%(15/58)in 10.0＜S/CO≤50.0 group,the positive rate was 82.09%(110/134)in 50.0＜S/CO≤500.0 group,and the positive rate was 99.25%(133/134)in S/CO＞500.0 group,there was statistical significance in the number of confirmed positives among the five groups(χ2=816.3,P<0.05).There were 473 confirmed negative cases,more women than men,the difference was statistically significant(χ2=98.3,P<0.05),among which the results of S/CO value≤10.0 accounted for 90.49%(428/473).There were 85 uncertain cases,the gender difference was not statistically significant(χ2=1.3,P>0.05),among which the results of S/CO value≤10.0 accounted for 72.94%(62/85).The positive bands gp120 and gp160 appeared in all the results,and p55 appeared the least,accounted for 51.91%(136/262).The uncertain bands were mainly p24,followed by gp160,etc.To a certain extent,the higher the S/CO value of chemiluminescence screening test,the more bands were present when the confirmative test was positive,and the more bands were present when the confirmative test was uncertain.Conclusion The higher the S/CO value of chemiluminescence test for HIV screening test,the higher the positive rate of the confirmation test and the more positive bands,they have practical value for laboratory analysis and early clinical diagnosis.

The clinical data of a case of Niemann-Pick disease type C diagnosed at Beijing Children′s Hospital, Capital Medical University on December 22, 2017 were retrospectively analyzed.The patient, male, 1 year and 28 days old, was admitted to the hospital primarily due to intermittent fever, cough and dyspnea for 8 months, and hepatosplenomegaly for 20 days.The patient initially presented with cough, expectoration, and wheezing, followed by hypotonia and delayed motor development.At the age of 1 year, the child developed hepatosplenomegaly and diffuse interstitial changes in both lungs.At the age of 3 years, the child had obvious vertical supranuclear gaze palsy and gelastic cataplexy, followed by dysarthria and dysphagia.The foam cells were found by bone marrow cytology, while sphingomyelinase and glucocerebrosidase were normal, so Niemann-Pick disease type A/B and Gaucher disease were excluded.Finally, genetic testing revealed two pathogenic mutations in the NPC1 gene, so Niemann-Pick disease type C was confirmed.Miglustat treatment began when the child was 3 years old, and vertical supranuclear gaze palsy and gelastic cataplexy improved for a while, but then the neurological symptoms worsened again, with dysphagia and dyspnea gradually increasing, and finally he died at the age of 4 years and 11 months.

This study aimed to analyze the clinical characteristics and prognosis of Takayasu′s arteritis (TA) with carotid artery occlusion in children. This study collected clinical data and follow-up information on the first diagnosis and treatment of c-TA combined with carotid artery occlusion in pediatric patients at the Children′s Hospital affiliated with the Capital Institute of Pediatrics and Inner Mongolia Medical University Affiliated Hospital from 2013 to 2023. This study included four female patients with a mean age of (13.25±1.71) years old. The time from onset to diagnosis was (8.14±11.19) months. Their main clinical symptoms and signs were dizziness, headache, chest discomfort, aphasia, dyskinesia, impaired mobility of the limbs, hypertension, asymmetry of blood pressure in the limbs, vascular murmurs or tremors, weakened radial artery pulsation, and decreased muscle strength. All four children showed elevated levels of C-reactive protein and erythrocyte sedimentation rate. The medical imaging results showed that among the four patients, three had bilateral carotid artery occlusion, and one had unilateral carotid artery occlusion. There were three cases of cerebrovascular involvement, accompanied by arterial involvement in multiple parts of the body, mainly involving bilateral subclavian arteries, cephalic trunk arteries, bilateral renal arteries, bilateral iliac arteries, and middle cerebral arteries. Four children were effectively treated with glucocorticoids and immunosuppressants. These children were followed up for a period of (42.25±52.54) months, which showed that the original affected artery still had varying degrees of occlusion, with no progression from the pre-treatment period and no new arterial involvement. The condition of three children with pre-existing physical and language disorders gradually improved. In summary, children with c-TA combined with carotid artery occlusion can cause involvement of multiple blood vessels. Their clinical manifestations are mostly systemic symptoms and ischemia of corresponding supply organs caused by vascular lesions, which are prone to be combined with cerebral infarction, and their occluded blood vessels are difficult to recover.

This study aimed to analyze the clinical characteristics and prognosis of Takayasu′s arteritis (TA) with carotid artery occlusion in children. This study collected clinical data and follow-up information on the first diagnosis and treatment of c-TA combined with carotid artery occlusion in pediatric patients at the Children′s Hospital affiliated with the Capital Institute of Pediatrics and Inner Mongolia Medical University Affiliated Hospital from 2013 to 2023. This study included four female patients with a mean age of (13.25±1.71) years old. The time from onset to diagnosis was (8.14±11.19) months. Their main clinical symptoms and signs were dizziness, headache, chest discomfort, aphasia, dyskinesia, impaired mobility of the limbs, hypertension, asymmetry of blood pressure in the limbs, vascular murmurs or tremors, weakened radial artery pulsation, and decreased muscle strength. All four children showed elevated levels of C-reactive protein and erythrocyte sedimentation rate. The medical imaging results showed that among the four patients, three had bilateral carotid artery occlusion, and one had unilateral carotid artery occlusion. There were three cases of cerebrovascular involvement, accompanied by arterial involvement in multiple parts of the body, mainly involving bilateral subclavian arteries, cephalic trunk arteries, bilateral renal arteries, bilateral iliac arteries, and middle cerebral arteries. Four children were effectively treated with glucocorticoids and immunosuppressants. These children were followed up for a period of (42.25±52.54) months, which showed that the original affected artery still had varying degrees of occlusion, with no progression from the pre-treatment period and no new arterial involvement. The condition of three children with pre-existing physical and language disorders gradually improved. In summary, children with c-TA combined with carotid artery occlusion can cause involvement of multiple blood vessels. Their clinical manifestations are mostly systemic symptoms and ischemia of corresponding supply organs caused by vascular lesions, which are prone to be combined with cerebral infarction, and their occluded blood vessels are difficult to recover.

China has classified the Corona Virus Disease 2019(COVID-19) as a statutory category B infectious disease and managed it according to Category B since January 8, 2023.In view that Omicron variant is currently the main epidemic strain in China, in order to guide the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection in children with the times, refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10 th Edition), Expert Consensus on Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fourth Edition) and the Diagnosis and Treatment Strategy for Pediatric Related Viral Infections.The Expert Consensus on the Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fifth Edition) has been formulated and updated accordingly on related etiology, epidemiology, pathogenic mechanism, clinical manifestations, auxiliary examination, diagnosis and treatment, and added key points for the treatment of COVID-19 related encephalopathy, fulminating myocarditis and other serious complications for clinical reference.

Objective:To assess the clinical effectiveness and safety of Omalizumab for treating pediatric allergic asthma in real world in China.Methods:The clinical data of children aged 6 to 11 years with allergic asthma who received Omalizumab treatment in 17 hospitals in China between July 6, 2018 and September 30, 2020 were retrospectively analyzed.Such information as the demographic characteristics, allergic history, family history, total immunoglobulin E (IgE) levels, specific IgE levels, skin prick test, exhaled nitric oxide (FeNO) levels, eosinophil (EOS) counts, and comorbidities at baseline were collected.Descriptive analysis of the Omalizumab treatment mode was made, and the difference in the first dose, injection frequency and course of treatment between the Omalizumab treatment mode and the mode recommended in the instruction was investigated.Global Evaluation of Treatment Effectiveness (GETE) analysis was made after Omalizumab treatment.The moderate-to-severe asthma exacerbation rate, inhaled corticosteroid (ICS) dose, lung functions were compared before and after Omalizumab treatment.Changes in the Childhood Asthma Control Test (C-ACT) and Pediatric Asthma Quality of Life Questionnaire (PAQLQ) results from baseline to 4, 8, 12, 16, 24, and 52 weeks after Omalizumab treatment were studied.The commodity improvement was assessed.The adverse event (AE) and serious adverse event (SAE) were analyzed for the evaluation of Omalizumab treatment safety.The difference in the annual rate of moderate-to-severe asthma exacerbation and ICS reduction was investigated by using t test.The significance level was set to 0.05.Other parameters were all subject to descriptive analysis.A total of 200 allergic asthma patients were enrolled, including 75.5% ( n=151) males and 24.5% ( n=49) females.The patients aged (8.20±1.81) years. Results:The median total IgE level of the 200 patients was 513.5 (24.4-11 600.0) IU/mL.Their median treatment time with Omalizumab was 112 (1-666) days.Their first dose of Omalizumab was 300 (150-600) mg.Of the 200 cases, 114 cases (57.0%) followed the first Omalizumab dosage recommended in the instruction.After 4-6 months of Omalizumab treatment, 88.5% of the patients enrolled ( n=117) responded to Omalizumab.After 4 weeks of treatment with Omalizumab, asthma was well-controlled, with an increased C-ACT score [from (22.70±3.70) points to (18.90±3.74) points at baseline]. Four-six months after Omalizumab administration, the annual rate of moderate-to-severe asthma exacerbation had a reduction of (2.00±5.68) per patient year( t=4.702 5, P<0.001), the median ICS daily dose was lowered [0 (0-240) μg vs. 160 (50-4 000) μg at baseline] ( P<0.001), the PAQLQ score was improved [(154.90±8.57) points vs. (122.80±27.15) points at baseline], and the forced expiratory volume in one second % predicted (FEV 1%pred) was increased [(92.80±10.50)% vs. (89.70±18.17)% at baseline]. In patients with available evaluations for comorbidities, including allergic rhinitis, atopic dermatitis or eczema, urticaria, allergic conjunctivitis and sinusitis, 92.8%-100.0% showed improved symptoms.A total of 124 AE were reported in 58 (29.0%) of the 200 patients, and the annual incidence was 0(0-15.1) per patient year.In 53 patients who suffered AE, 44 patients (83.0%) and 9 patients (17.0%) reported mild and moderate AE, respectively.No severe AE were observed in patients.The annual incidence of SAE was 0(0-1.9) per patient year.Most common drug-related AE were abdominal pain (2 patients, 1.0%) and fever (2 patients, 1.0%). No patient withdrew Omalizumab due to AE. Conclusions:Omalizumab shows good effectiveness and safety for the treatment of asthma in children.It can reduce the moderate-to-severe asthma exacerbation rate, reduce the ICS dose, improve asthma control levels, and improve lung functions and quality of life of patients.

Background:Antibiotics can reduce the efficacy of immunotherapy for melanoma,non-small cell lung cancer and renal cell carcinoma by altering the intestinal microbiome,but their effect in the treatment of gastrointestinal cancer is unclear.Aims:To investigate the prognostic effect of antibiotics on PD-1/PD-L1 inhibitors in the treatment of colorectal cancer(CRC)patients.Methods:The clinicopathological data of 95 patients diagnosed with CRC and treated with immune checkpoint inhibitors(ICIs)from December 2018 to May 2022 at Renmin Hospital of Wuhan University were retrospectively analyzed,and the patients were divided into antibiotic group and control group according to whether antibiotics were used.Risk factors of progression free survival(PFS)and overall survival(OS)were analyzed by univariate and multivariate analysis.Results:Among the 95 patients with CRC,64 were male and 31 were female.The mean age was(60.46±11.82)years.PFS(10.9 months vs.24.8 months,P=0.032)and OS(14.5 months vs.35.5 months,P=0.008)were significantly decreased in antibiotic group than in control group,and one-year survival rate was 56.5%and 78.7%,respectively.Multivariate analysis showed that tumor location and antibiotic use were independent risk factors of PFS(P<0.05),while tumor location,antibiotic use and no radical surgery were independent risk factors of OS(P<0.05).Univariate and multivariate analyses showed that antibiotic administration route,dose were not risk factors of PFS(P>0.05);univariate analysis showed that antibiotic administration route was correlated with OS(P=0.045),however,multivariate analysis showed that antibiotic administration route,infection location were not risk factors of OS(P>0.05).Conclusions:Tumors located in colon and antibiotics applied within 30 days before and after the first dose of ICIs can shorten PFS and OS in CRC patients,while radical surgery can prolong the OS of CRC patients.

Objective:To explore the clinical features, follow-up characteristics and prognosis of rheumatic disease complicated with pulmonary arterial hypertension (PAH) in children, and to provide support for its clinical diagnosis and treatment.Methods:A retrospective analysis was conducted on the data of rheumatic 24 patients complicated with PAH hospitalized in the Department of Rheumatology and Immunology, Children′s Hospital Affiliated to the Capital Institute of Pediatrics, Department of Rheumatology and Immunology, Jiangxi Children′s Hospital, Department of Pediatrics Ⅰ, the First Affiliated Hospital of Zhengzhou University and Department of Pediatrics, the Affiliated Hospital of Inner Mongolia Medical University from January 2013 to June 2022.The rheumatic patients complicated with PAH were followed up by telephone on June 30, 2022, and their clinical symptoms, treatment, follow-up, and prognosis data were collected.According to different treatment methods, the patients were divided into different clinical subgroups. The change of PAH was analyzed. The t-test was used for comparison between groups. P<0.05 was statistically significant. Results:A total of 24 cases were enrolled, with 7 males and 17 females.The average onset age of PAH was (10.97±3.79) years old.The median duration of PAH was 6.00 (32.20) months.The average pulmonary artery pressure was (51.71±17.66) mmHg(1 mmHg=0.133 kPa). There were 9 cases of systemic lupus erythematosus, 5 cases of Takayasu′s arteritis, 3 cases of juvenile dermatomyositis, 3 cases of undifferentiated connective tissue disease, 2 cases of systemic juvenile idiopathic arthritis, 1 case of Behcet′s disease, and 1 case of Kawasaki disease.Among 24 cases, the common symptoms were fever (14 cases), fatigue (10 cases) and dyspnea (7 cases). Of the 24 cases, 10 cases were complicated with hydropericardium, 9 cases with valve regurgitation, and 5 cases with decreased systolic and/or diastolic function.Lung changes were observed in 17 cases.Eleven cases were tested for B-type natriuretic peptide (BNP), and the BNP levels were all elevated in them (11 cases), with a median BNP of 3 073 (10 645) ng/L.After the first occurrence of PAH, 12 cases were treated with Methylprednisolone therapy, 10 cases received Cyclophosphamide therapy, and 2 cases who were both systemic lupus erythematosus, underwent blood purification.In the treatment of PAH, 11 cases were treated with pulmonary artery pressure reduction, and 7 of the 11 cases took PAH-targeted drugs.The mean decrease of the average pulmonary artery pressure in children receiving the targeted therapy[(44.80±24.08) mmHg] was significant higher than that in children not receiving the targeted therapy [(16.15±17.25) mmHg] ( t=2.661, P=0.016). Twenty children were reexamined and/or followed up, and the average course of PAH at the telephone follow-up was (36.29±26.67) months.The pulmonary arterial hypertension in 6 cases completely recovered, with median recovery time of 8.00 (13.47) months, but 2 of them died after the complete recovery.The pulmonary arterial hypertension improved in 11 children, 1 of whom died and the remaining children were in stable condition.The pulmonary arterial hypertension worsened in 2 children, 1 of them improved previously but aggravated recently, and the other child did not monitor pulmonary artery pressure and died during telephone follow-up. Conclusions:Rheumatic diseases complicated with PAH are rare and most often diagnosed in severe rheumatic children.It can lead to death, and is commonly accompanied by notably elevated BNP levels.The patients who have early PAH detection, intensive treatment of the primary disease, symptomatic and targeted pulmonary artery pressure reduction show a better prognosis.

Objective:A case of cystic fibrosis admitted in the Respiratory Department of Beijing Children′s Hospital, Capital Medical University in June 2018 and underwent lung transplantation later was analyzed retrospectively.A 10-year-old girl had intermittent productive cough for more than 4 years with clubbed-finger.The lung high resolution CT (HRCT) showed bronchiectasis and mucus impaction, and the nasal sinus HRCT showed sinusitis.She had cystic fibrosis transmembrane conductance regulator ( CFTR) gene complex heterozygous mutation and positive sweat test.The immunoglobulin E (IgE) level and eosinophil count increased, and aspergillus fumigatus-specific IgE was positive.She was diagnosed as cystic fibrosis, allergic bronchopulmonary aspergillosis and sinusitis.Anti-infection, glucocorticoid and symptomatic treatment were given.During the following 21 months, the child had repeated respiratory difficulties and respiratory failure.Her lung function declined.Bilateral lung transplantation was performed in March 2020.She had a good recovery at more than 1 year and 3 months postoperatively.